Dudediligence.

Axsome Therapeutics, Inc

AXSMNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$104.8MSep ’24$118.8MDec ’24$121.5MMar ’25$150.0MJun ’25$171.0MSep ’25$196.0MDec ’25$191.2MMar ’26$218.4MJun ’26
Net income, by quarter
−$64.6MSep ’24−$74.9MDec ’24−$59.4MMar ’25−$48.0MJun ’25−$47.2MSep ’25−$28.6MDec ’25−$64.5MMar ’26−$51.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$50.0M$270.6M$385.7M$638.5M
Gross profitnone on file$44.8Mnone on filenone on filenone on file
Operating income−$124.7M−$179.8M−$231.8M−$280.6M−$166.8M
Net income−$130.4M−$187.1M−$239.2M−$287.2M−$183.2M
Operating cash flow−$108.2M−$116.5M−$145.1M−$128.4M−$93.4M
Free cash flow−$108.5M−$117.2M−$145.7M−$128.7M−$93.9M
Cash$86.5M$200.8M$386.2M$315.4M$322.9M
Debt$49.1M$94.3M$178.1M$180.7M$187.7M
Shares outstanding37.8M43.5M47.4M48.7M50.9M